Immix Biopharma Announces Early Positive IMX-110 Interim …
May 3, 2023 · The novel approach combining TSTx IMX-110 with anti-PD-1 antibody tislelizumab is designed to expand the population of cancer patients experiencing extended remissions from immunotherapies by converting immunologically “cold” tumors “hot”.
IMX-110/Tislelizumab Yields Notable Tumor Shrinkage in Two …
May 5, 2023 · Immix Biopharma announces early positive IMX-110 interim clinical trial data demonstrating 100% tumor shrinkage in advanced metastatic colorectal cancer at the lowest dose of IMX-110 + BeiGene / Novartis anti-PD-1 antibody tislelizumab.
Immix Biopharma Announces 16th Patient Dosing in Ongoing …
Dec 20, 2022 · This is the sixteenth patient dosed with IMX-110 to-date, and the second patient dosed so far in December 2022. This patient has a relapsed/refractory pecoma, a rare form of soft tissue sarcoma, a connective tissue cancer.
IMX-110 Granted Rare Pediatric Disease Designation by FDA …
Jan 5, 2022 · IMX-110 is a tissue-specific therapeutic that simultaneously attacks all 3 components of the tumor micro-environment, severing the critical lifelines between the tumor and its metabolic and structural support.
ImmixBio Announces FDA Orphan Drug Designation for IMX-110 …
Sep 30, 2021 · IMX-110 is a Tissue-Specific Therapeutic TM built on ImmixBio's TME Normalization TM Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor...
IMX-110 Plus Tislelizumab Shows Early Activity in Advanced
May 3, 2023 · Immix Biopharma announces early positive IMX-110 interim clinical trial data demonstrating 100% tumor shrinkage in advanced metastatic colorectal cancer at the lowest dose of IMX-110 +...
Immix reports positive interim results from cancer therapy trial
May 4, 2023 · Immix Biopharma has reported early positive interim data from its ongoing Phase Ib/IIa dose escalation clinical trial IMMINENT-01 of IMX-110 for the treatment of advanced metastatic colorectal cancer.
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim
Jan 19, 2022 · Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation...
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim …
Jan 19, 2022 · Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma, a life-threatening form of …
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 ...
Feb 7, 2023 · Immix Biopharma, Inc. today announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in patients with advanced solid tumors.
- Some results have been removed